Month: July 2020

LATHAM, N.Y., July 30, 2020 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ:PLUG), a leading provider of zero emission hydrogen engines and fueling solutions enabling e-mobility, will announce 2020 second quarter results on August 6, 2020.In conjunction with the issued results, the Company will host a live conference call and webcast.Join the call:Date: Thursday, August 6, 2020Time: 10:00 am ETParticipant Dial-In: 877-405-1239 / 201-389-0851Direct webcast: https://event.webcasts.com/starthere.jsp?ei=1351078&tp_key=c7fe17e5faThe webcast can also be accessed at www.plugpower.com, selecting the conference call link on the home page. A playback of the call will be available online for a period following the event.About Plug Power Inc.Plug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell...

THE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020.“We achieved 21% growth in XERMELO net sales in the U.S. for the second quarter of 2020 compared to the prior-year period, underscoring the importance of our product to patients,” said Lonnel Coats, Lexicon’s president and chief executive officer. “In these unprecedented times of the COVID-19 pandemic, I am proud of the commitment and dedication of our employees to our mission to pioneer medicines to transform patients’ lives. We continue to make progress on our pipeline with initiation of screening of patients in the Phase 2 RELIEF-DPN-1 study for LX9211 in patients with diabetic peripheral neuropathic pain. We look forward to...

NEWARK, N.Y., July 30, 2020 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.3 million on revenue of $28.6 million for the second quarter ended June 30, 2020. For the second quarter of 2019, the Company reported operating income of $3.0 million on revenue of $29.4 million.“Ultralife’s second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic,” said Michael D. Popielec, President and Chief Executive Officer. “Our Battery and Energy Products’ medical sales and government/defense sales increased 72% and 50% year over year, respectively, and when combined with the contribution from SWE, nearly offset Communications Systems sales which were lower due...

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern TimeNEW YORK, July 30, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2020 on Monday, August 10, 2020 before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 AM Eastern Time on August 10, 2020 to discuss these results and provide a business update.To participate in the live conference call, please dial (844) 698-4029 (toll-free domestic) or (647) 253-8660 (international), and use the conference ID 4876676. A live webcast of the conference call can be accessed on the “Webcasts...

RIDGEFIELD PARK, NEW JERSEY, July 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — LIFEQUEST WORLD CORP (LQWC) today announced the appointment of TraDigital IR, a leading financial and digital media communications firm, as its investor relations advisor.Max Khan, CEO of Lifequest, commented, “We are pleased to appoint TraDigital as our investor relations advisor. TraDigital’s industry expertise and capital market knowledge will assist Lifequest in its efforts to strengthen our communication with investors and improve market awareness of our company. We look forward to working closely with TraDigital to convey our business story, growth strategy, competitive advantages, and value proposition to the investment community.”  “Our team is excited about having been appointed IR advisor to Lifequest,” said MJ Clyburn, founder...

First call achieved within 25 days of Nokia software deployment, surpassing the performance of other solutions in the marketCall underscores the interoperability of Nokia Software products, irrespective of hardware environment30 July 2020 Espoo, Finland – Nokia today announced that it has successfully completed its first 5G standalone (SA) call on a live network with China Unicom, and is expected to achieve full deployment of numerous software solutions with the operator several weeks ahead of schedule.The data and voice calls, which marked firsts for Nokia on a 5G SA network, were completed earlier than planned in part due to Nokia’s experience-driven, customer-focused approach. By bypassing non-standalone (NSA) 5G core deployments entirely, Nokia was able to deliver 5G SA core for China Unicom and enable crucial network functions, such...

ZION, Il, July 30, 2020 (GLOBE NEWSWIRE) — Lifted Made, a wholly owned subsidiary of publicly traded Acquired Sales Corp. (OTC Pink: AQSP), is excited to announce its launch of flavored nano CBD water enhancer packets under Lifted Made’s flagship brand Urb Finest Flowers (Instagram @LiftedMade).Urb’s nano CBD water enhancer packets are water soluble and are available in four delicious flavors: mango, blue razz, watermelon and lemon. Each packet  contains approximately 10 mg. of CBD, and less than 0.3% delta-9-THC. The packets are for sale in a box of 24 for $71.76 ($2.99 each). The packets are available for purchase online at www.LiftedMade.com and will be distributed to brick and mortar stores throughout the USA.Nicholas S. Warrender, CEO of Lifted Made, and Vice Chairman and COO of Acquired Sales Corp., commented: “Urb’s nano...

Richland WA, July 30, 2020 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB: RDGL), Interest in IsoPet therapy is increasing. Yesterday Vivos Inc treated “Mister Motto” a cat that the pet parents flew to the state of Washington from New York City. As interest and awareness continues to increase, pet parents are making it a priority to obtain therapy even with the challenges presented by the Corona Virus. The owner of our previous patient drove twelve hours from California and we are pleased to report that the large spindle cell tumor decreased 30% in size in five weeks.Dr. Mike Korenko stated “Over the last twelve months we have had expressions of Interest for IsoPet therapy for patients in thirteen states, Vancouver BC and Montreal Canada. Over time word is spreading on the IsoPet therapy. We will continue to publish our results and will present...

REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update.We encourage participants to pre-register for the conference call using the following link: http://dpregister.com/10146500. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.Those without internet access or unable to pre-register may dial in...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia. The FDA previously granted Orphan Drug designation for IMR-687 for the treatment of patients with beta-thalassemia and Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of patients with sickle cell disease.“We are pleased to receive from the FDA both Fast Track designation and Rare Pediatric Disease designation for IMR-687. Fast Track designation...